Last 12 months
Inside the activity.
1 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Freeman Roy LesterDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 9 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires 2030-06-30 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Freeman Roy LesterDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 8 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2029-06-24 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Freeman Roy LesterDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 7 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires 2029-06-24 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Freeman Roy LesterDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,780 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 6 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,780 Underlying: Common Stock · 3,780 shares Expires 2028-06-25 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Freeman Roy LesterDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 3,780 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 5 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,780 shares Expires 2028-06-25 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Freeman Roy LesterDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,138 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 4 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,138 Underlying: Common Stock · 1,138 shares Expires 2027-12-22 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Freeman Roy LesterDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 1,138 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 3 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,138 shares Expires 2027-12-22 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F4 · derivative.expiration_date: The acquisition of the reported option was reported in a Form 4 filed on December 29, 2020, which mistakenly reported the expiration date as December 22, 2030. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Freeman Roy LesterDirector
|
GrantStock Option (Right to Buy) · Derivative | 21,854 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 2 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,854 Underlying: Common Stock · 21,854 shares Expires 2026-07-28 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Freeman Roy LesterDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 21,854 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 1 Freeman Roy Lester · CIK 0001799732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,854 shares Expires 2026-07-28 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
BERMAN DENNIS NDirector
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007744 · ownership.xml · derivative · entry 12 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Molino Ventures, LLC Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-07-16 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
BERMAN DENNIS NDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000950170-25-007744 · ownership.xml · derivative · entry 11 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Molino Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2031-07-16 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
BERMAN DENNIS NDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007744 · ownership.xml · derivative · entry 10 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Molino Ventures, LLC Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2030-06-30 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
BERMAN DENNIS NDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000950170-25-007744 · ownership.xml · derivative · entry 9 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Molino Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires 2030-06-30 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
BERMAN DENNIS NDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007744 · ownership.xml · derivative · entry 8 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Molino Ventures, LLC Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2029-06-24 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
BERMAN DENNIS NDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0000950170-25-007744 · ownership.xml · derivative · entry 7 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Molino Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires 2029-06-24 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
BERMAN DENNIS NDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,780 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007744 · ownership.xml · derivative · entry 6 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Molino Ventures, LLC Disclosed balance after: 3,780 Underlying: Common Stock · 3,780 shares Expires 2028-06-25 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
BERMAN DENNIS NDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 3,780 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0000950170-25-007744 · ownership.xml · derivative · entry 5 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Molino Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 3,780 shares Expires 2028-06-25 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
BERMAN DENNIS NDirector
|
GrantStock Option (Right to Buy) · Derivative | 1,138 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007744 · ownership.xml · derivative · entry 4 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,138 Underlying: Common Stock · 1,138 shares Expires 2027-12-22 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
BERMAN DENNIS NDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 1,138 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0000950170-25-007744 · ownership.xml · derivative · entry 3 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,138 shares Expires 2027-12-22 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F4 · derivative.expiration_date: The acquisition of the reported option was reported in a Form 4 filed on December 29, 2020, which mistakenly reported the expiration date as December 22, 2030. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
BERMAN DENNIS NDirector
|
GrantStock Option (Right to Buy) · Derivative | 21,854 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007744 · ownership.xml · derivative · entry 2 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Molino Ventures, LLC Disclosed balance after: 21,854 Underlying: Common Stock · 21,854 shares Expires 2026-08-31 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
BERMAN DENNIS NDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 21,854 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0000950170-25-007744 · ownership.xml · derivative · entry 1 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Molino Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 21,854 shares Expires 2026-08-31 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 18 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-04-01 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 17 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2031-04-01 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 16 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-03-01 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 15 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2030-03-01 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 20,834 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 14 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,834 Underlying: Common Stock · 20,834 shares Expires 2029-03-07 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 20,834 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 13 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,834 shares Expires 2029-03-07 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 16,667 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 12 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2030-12-22 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 16,667 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 11 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires 2030-12-22 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 3,643 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 10 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,643 Underlying: Common Stock · 3,643 shares Expires 2029-11-01 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 3,643 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 9 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,643 shares Expires 2029-11-01 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 3,643 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 8 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,643 Underlying: Common Stock · 3,643 shares Expires 2028-11-01 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 3,643 | $0.00 Strike: $28.76 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 7 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,643 shares Expires 2028-11-01 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 3,643 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 6 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,643 Underlying: Common Stock · 3,643 shares Expires 2027-11-01 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 3,643 | $0.00 Strike: $13.86 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 5 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,643 shares Expires 2027-11-01 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 3,643 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 4 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,643 Underlying: Common Stock · 3,643 shares Expires 2026-11-01 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 3,643 | $0.00 Strike: $13.86 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 3 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,643 shares Expires 2026-11-01 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 3,643 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 2 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,643 Underlying: Common Stock · 3,643 shares Expires 2025-11-01 F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC |
Werner Milton H.Director · President and CEO
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 3,643 | $0.00 Strike: $13.86 | $0.00 |
DisclosureSEC source: 0000950170-25-007741 · ownership.xml · derivative · entry 1 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,643 shares Expires 2025-11-01 F1 · derivative.exercise_price: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. Read SEC document |
| January 21, 2025 Filed Feb 20, 2025 01:06 UTC Amendment |
BERMAN DENNIS NDirector
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-023572 · ownership.xml · derivative · entry 5 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-07-16 F3 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · ownership.direct: The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported. Read SEC document |
| January 21, 2025 Filed Feb 20, 2025 01:06 UTC Amendment |
BERMAN DENNIS NDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-023572 · ownership.xml · derivative · entry 4 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2030-06-30 F3 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F1 · ownership.direct: The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported. Read SEC document |
| January 21, 2025 Filed Feb 20, 2025 01:06 UTC Amendment |
BERMAN DENNIS NDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-023572 · ownership.xml · derivative · entry 3 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2029-06-24 F3 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F3 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · ownership.direct: The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported. Read SEC document |
| January 21, 2025 Filed Feb 20, 2025 01:06 UTC Amendment |
BERMAN DENNIS NDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,780 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-023572 · ownership.xml · derivative · entry 2 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,780 Underlying: Common Stock · 3,780 shares Expires 2028-06-25 F3 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F3 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · ownership.direct: The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported. Read SEC document |
| January 21, 2025 Filed Feb 20, 2025 01:06 UTC Amendment |
BERMAN DENNIS NDirector
|
GrantStock Option (Right to Buy) · Derivative | 21,854 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-023572 · ownership.xml · derivative · entry 1 BERMAN DENNIS N · CIK 0001273858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,854 Underlying: Common Stock · 21,854 shares Expires 2026-08-31 F3 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F3 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.underlying_shares: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F2 · balance_after: The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023. F1 · ownership.direct: The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 18:43 UTC |
Lees-Rolfe GarthChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 432,853 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0000950170-25-003130 · ownership.xml · derivative · entry 3 Lees-Rolfe Garth · CIK 0002017374 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,853 Underlying: Common Stock · 432,853 shares Expires 2035-01-03 F3 · derivative.exercise_date: The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 18:43 UTC |
Lees-Rolfe GarthChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 235,383 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0000950170-25-003130 · ownership.xml · derivative · entry 2 Lees-Rolfe Garth · CIK 0002017374 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,383 Underlying: Common Stock · 235,383 shares Expires 2035-01-03 F2 · derivative.exercise_date: The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series A-1 Warrants in an amount proportional to the actual number of Series A-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 18:43 UTC |
Lees-Rolfe GarthChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 470,861 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-003130 · ownership.xml · derivative · entry 1 Lees-Rolfe Garth · CIK 0002017374 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 470,861 Underlying: Common Stock · 470,861 shares Expires 2035-01-03 F1 · derivative.exercise_date: The options vested and became exercisable on October 9, 2024. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:47 UTC |
Werner Milton H.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 4,059,744 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0000950170-25-003132 · ownership.xml · derivative · entry 3 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,059,744 Underlying: Common Stock · 4,059,744 shares Expires 2035-01-03 F3 · derivative.exercise_date: The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:47 UTC |
Werner Milton H.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 2,207,671 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0000950170-25-003132 · ownership.xml · derivative · entry 2 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,207,671 Underlying: Common Stock · 2,207,671 shares Expires 2035-01-03 F2 · derivative.exercise_date: The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series A-1 Warrants in an amount proportional to the actual number of Series A-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 23:47 UTC |
Werner Milton H.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 5,315,056 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0000950170-25-003132 · ownership.xml · derivative · entry 1 Werner Milton H. · CIK 0001827621 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,315,056 Underlying: Common Stock · 5,315,056 shares Expires 2035-01-03 F1 · derivative.exercise_date: The options vested and became exercisable on October 9, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.